Literature DB >> 3351804

Sexually transmitted diseases and the risk of tubal pregnancy.

K J Sherman1, W H Chow, J R Daling, N S Weiss.   

Abstract

Women who were hospitalized for tubal pregnancy in five hospitals in King County, Washington, between 1975 and 1979 were interviewed regarding a prior history of gonorrhea, genital herpes, genital warts and trichomoniasis. Their responses were compared to those of women who delivered a live-born child during the same period. Multiple logistic regression was used to control for the effects of race, gravidity, smoking, Dalkon Shield use, douching, number of sexual partners and history of additional sexually transmitted diseases. The risk of tubal pregnancy in women who reported a history of gonorrhea, relative to that in other women, was 5.1. As compared to controls, women with tubal pregnancy more often reported a history of genital herpes and a history of trichomoniasis.

Entities:  

Keywords:  Bias; Data Analysis; Data Collection; Diseases; Error Sources; Infections; Measurement; Population At Risk; Pregnancy Complications; Pregnancy, Ectopic; Pregnancy, Tubal; Reliability; Reproductive Tract Infections; Research Methodology; Sexually Transmitted Diseases--history

Mesh:

Year:  1988        PMID: 3351804

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  3 in total

1.  Trichomonas vaginalis infection: can we afford to do nothing?

Authors:  R Scott McClelland
Journal:  J Infect Dis       Date:  2008-02-15       Impact factor: 5.226

2.  Adherence to human vaginal epithelial cells signals for increased expression of Trichomonas vaginalis genes.

Authors:  Ashwini S Kucknoor; Vasanthakrishna Mundodi; J F Alderete
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

3.  Heterologous expression in Tritrichomonas foetus of functional Trichomonas vaginalis AP65 adhesin.

Authors:  Ashwini S Kucknoor; Vasanthakrishna Mundodi; J F Alderete
Journal:  BMC Mol Biol       Date:  2005-03-04       Impact factor: 2.946

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.